Last edition
News about Global Pharma
ScreenPoint Medical to Showcase New Transpara Breast AI Features at 2025 SBI Symposium
ScreenPoint Medical will showcase innovative new capabilities of its industry leading Breast AI, Transpara®, at the 2025 Society of Breast Imaging Symposium, April 24-27, 2025 (Booth #330).
Global Pharma | 16/04/2025 | By Manvi | 327
Steriline to Debut at Pharmintech 2025 with Innovative Filling and Capping Machine
The unit presented by Steriline at Pharmintech 2025 is the RVFCM11-S, an extremely compact (2.25 m by 1.65 m), advanced robotic solution designed specifically for the primary packaging of drugs for cell and gene therapies.
Global Pharma | 16/04/2025 | By Manvi | 440
Chime Biologics, Polpharma Biologics Join Hands to Advance Global Biosimilar Development
Chime Biologics has entered a strategic cooperation agreement with Polpharma Biologics to support end-to-end development and manufacturing of a biosimilar product for global markets.
Global Pharma | 16/04/2025 | By Manvi | 228
Nikon CeLL Innovation Enters into Strategic Licensing Agreement with RoosterBio
Nikon CeLL Innovation has signed a strategic licensing agreement with US-based RoosterBio to bring a scalable manufacturing platform for mesenchymal stem cell and extracellular vesicle therapies to Japan.
Global Pharma | 16/04/2025 | By Manvi | 344
Terumo Neuro Secures FDA Premarket Approval for Carotid Stent System
Terumo Neuro's Carotid Stent System is indicated for the treatment of carotid artery stenosis in patients at increased risk for adverse events following carotid endarterectomy.
Global Pharma | 16/04/2025 | By Abha | 445
The system is prepared for magnetic tracking and navigation of third-party catheters, which in the future, will further empower clinicians to perform complex procedures with greater precision and control.
Global Pharma | 16/04/2025 | By Abha | 216
First-in-Human Trial of VAS-101 Topical Curcumin Gel for Sickle Cell Disease Begins in Florida
Ten (10) patients with sickle cell disease will be treated with VAS-101 twice per week over 4 weeks for a total of 8 treatments; their blood will be drawn weekly.
Global Pharma | 15/04/2025 | By Manvi | 320
Norgine Acquires Theravia, Expands Rare Disease Portfolio
Norgine has entered into a definitive agreement to acquire Theravia, enhancing its rare disease portfolio with established treatments in rare haematology and hepatology.
Global Pharma | 15/04/2025 | By Manvi | 338
Biocon Biologics Secures Market Entry Date for Yesafili in US
Biocon Biologics has signed a settlement and license agreement with Regeneron, paving the way to launch its interchangeable aflibercept biosimilar, YESAFILI, in the US by the second half of 2026.
Global Pharma | 15/04/2025 | By Manvi | 228
ActiveProtective Launches FDA-Approved Tango Belt to Prevent Hip Injuries in Older Adults
The Tango Belt, having already received Breakthrough Device Designation by the US Food and Drug Administration (FDA), was further granted marketing authorization as a prescription-only device intended as an adjunctive to standard-of-care to reduce the risk of hip fracture or hip dislocation due to falls in older adults at risk of major hip injury due
Global Pharma | 15/04/2025 | By Manvi | 344
We use our own and third party cookies to produce statistical information and show you personalized advertising by analyzing your browsing, according to our COOKIES POLICY. If you continue visiting our Site, you accept its use.
More information: Privacy Policy